Photocure ASA
OSE:PHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SciVision Biotech Inc
TWSE:1786
|
TW |
|
Top Shelf International Holdings Ltd
ASX:TSI
|
AU |
|
GSE Systems Inc
NASDAQ:GVP
|
US |
|
M
|
My EG Services Bhd
KLSE:MYEG
|
MY |
|
M
|
Mudanjiang Hengfeng Paper Co Ltd
SSE:600356
|
CN |
|
Cr Credit Agricole Mutuel Loire Hte Loir
PAR:CRLO
|
FR |
|
T
|
TC Energy Corp
NYSE:TRP
|
CA |
|
Empresa Distribuidora y Comercializadora Norte SA
NYSE:EDN
|
AR |
|
C
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SSE:601512
|
CN |
|
SNL Bearings Ltd
BSE:505827
|
IN |
|
S
|
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
|
CN |
|
MIC Electronics Ltd
NSE:MICEL
|
IN |
|
K
|
Kennametal India Ltd
NSE:KENNAMET
|
IN |
|
Rifa Co Ltd
KRX:000760
|
KR |
|
Amcor PLC
NYSE:AMCR
|
UK |
Photocure ASA
EPS (Diluted)
Photocure ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
EPS (Diluted)
kr0
|
CAGR 3-Years
72%
|
CAGR 5-Years
42%
|
CAGR 10-Years
28%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
EPS (Diluted)
kr1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
EPS (Diluted)
kr0
|
CAGR 3-Years
88%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncoinvent ASA
OSE:ONCIN
|
EPS (Diluted)
-kr176
|
CAGR 3-Years
-661%
|
CAGR 5-Years
-256%
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's EPS (Diluted)?
EPS (Diluted)
-0.1
NOK
Based on the financial report for Dec 31, 2025, Photocure ASA's EPS (Diluted) amounts to -0.1 NOK.
What is Photocure ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
28%
Over the last year, the EPS (Diluted) growth was 50%. The average annual EPS (Diluted) growth rates for Photocure ASA have been 72% over the past three years , 42% over the past five years , and 28% over the past ten years .
